Author(s):
Liji Jacob, Manju Salim S, Jilby Saju
Email(s):
lijivjacob@gmail.com
DOI:
10.52711/2231-5713.2022.00016 
Address:
Liji Jacob, Manju Salim S, Jilby Saju
Department of Pharmaceutics, Al-Azhar College of Pharmacy, Perumpillychira - 685605, Thodupuzha, Kerala, India.
*Corresponding Author
Published In:
Volume - 12,
Issue - 2,
Year - 2022
ABSTRACT:
Selegiline is an antiparkinsonian drug. It is a MAO-B enzyme inhibitor. It undergoes hepatic first pass metabolism and it result in 10% bioavailability on oral administration. So it was designed to formulate transdermal patches of Selegiline HCl for enhancing the bioavailability and patient compliance. Different formulation were prepared by different grades and varying concentration of polymer by solvent casting method. PG was used as permeation enhancer. The films were subjected to evaluation parameters like weight variation, thickness, moisture content, tensile strength, folding endurance, drug content and in-vitro drug release.
Cite this article:
Liji Jacob, Manju Salim S, Jilby Saju. Formulation and Evaluation of Transdermal Patches of Selegiline. Asian Journal of Pharmacy and Technology. 2022; 12(2):96-0. doi: 10.52711/2231-5713.2022.00016
Cite(Electronic):
Liji Jacob, Manju Salim S, Jilby Saju. Formulation and Evaluation of Transdermal Patches of Selegiline. Asian Journal of Pharmacy and Technology. 2022; 12(2):96-0. doi: 10.52711/2231-5713.2022.00016 Available on: https://ajptonline.com/AbstractView.aspx?PID=2022-12-2-2
REFERENCES:
1. Prabhakar D, Sreekanth J, Jayaveera KN. Transdermal drug delivery patches: a review. J Drug Deliv Ther. 2013;3(4):213–21.
2. Jalwal P, Jangra A, Dhaiya L, Sangwan Y, Saroha R. A review on transdermal patches. Pharm Res. J. 2010; 3:139-149.
3. Yadav V. Transdermal drug delivery system: review. Int. J Pharm Sci. Res. 2012;3(2):376-382.
4. Dhiman S, Thakur GS, Rehni AK. Transdermal patches: a recent approach to new drug delivery system. Int. J Pharmacy Pharm Sci. 2011;3(5):26-34.
5. Sharma RK, Keleb E, Mosa EB, Aljahwi AAZ. Transdermal drug delivery system- design and evaluation. Int. J Advances Pharm Sci. 2010; 1: 201-211.
6. Sandhu P, Bilandi A, Kataria S, Middha A. Transdermal drug delivery system (patches), applications in present scenario. Int. J Res. Pharm Chem. 2011;1(4):1139-1151.
7. Patel D, Chaudhary SA, Parmar B, Bhura N. Transdermal drug delivery system: a review. The Pharm Innovation. 2012;1(4):66-75.
8. “Selegiline from wikipedia, the free encyclopedia,” http:// en.wikipedia.org/wiki/Selegiline.
9. K. C. Garala, A. J. Shinde, and P. H. Shah, “Formulation and in-vitro characterization of monolithic matrix transdermal systems using HPMC/Eudragit S 100 polymer blends,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 1, no. 1, pp. 108–120, 2009.
10. A. Shivaraj, R. Panner Selvam, T. Tamiz Mani, and T. Sivakumar, “Design and evaluation of transdermal drug delivery of ketotifen fumarate,” International Journal of Pharmaceutical and Biomedical Research, vol. 1, no. 2, pp. 42–47, 2010.
11. E. Keleb, R. Sharma, E. B. Mosa, and A. Z. Zaljahwi, “Transdermal drug delivery system- design and evaluation,” International Journal of Advances in Pharmaceutical Sciences, vol. 1, pp. 201–211, 2010.
12. S. T. Lec, S. H. Yac, S. W. Kim, and B. Berner, “One-way membrane for transdermal drug delivery system. II. System optimization,” International Journal of Pharmaceutics, vol. 77, no. 2-3, pp. 231–237, 1991.
13. Gupta JRD, Tripathi P, Irchhiaya R, Garud N, Dubey P, Patel JR. Skin permeation advancements. Int J Pharm Sci Drug Res. 2009; 1: 146–150.
14. Mohammed Gulzar Ahmed, Kiran Kumar GB and Satish Kumar BP. Formulation and Evaluation of Nifedipine Transdermal Patches. J. of Pharm. Research., 3(8), 2010, 1785-1787.